JP2012201599A5 - - Google Patents

Download PDF

Info

Publication number
JP2012201599A5
JP2012201599A5 JP2011064911A JP2011064911A JP2012201599A5 JP 2012201599 A5 JP2012201599 A5 JP 2012201599A5 JP 2011064911 A JP2011064911 A JP 2011064911A JP 2011064911 A JP2011064911 A JP 2011064911A JP 2012201599 A5 JP2012201599 A5 JP 2012201599A5
Authority
JP
Japan
Prior art keywords
propionic acid
blood cholesterol
cholesterol
reducing agent
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011064911A
Other languages
English (en)
Japanese (ja)
Other versions
JP5818309B2 (ja
JP2012201599A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2011064911A priority Critical patent/JP5818309B2/ja
Priority claimed from JP2011064911A external-priority patent/JP5818309B2/ja
Publication of JP2012201599A publication Critical patent/JP2012201599A/ja
Publication of JP2012201599A5 publication Critical patent/JP2012201599A5/ja
Application granted granted Critical
Publication of JP5818309B2 publication Critical patent/JP5818309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011064911A 2011-03-23 2011-03-23 血中コレステロール低減剤 Active JP5818309B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011064911A JP5818309B2 (ja) 2011-03-23 2011-03-23 血中コレステロール低減剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011064911A JP5818309B2 (ja) 2011-03-23 2011-03-23 血中コレステロール低減剤

Publications (3)

Publication Number Publication Date
JP2012201599A JP2012201599A (ja) 2012-10-22
JP2012201599A5 true JP2012201599A5 (enExample) 2014-04-03
JP5818309B2 JP5818309B2 (ja) 2015-11-18

Family

ID=47182952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011064911A Active JP5818309B2 (ja) 2011-03-23 2011-03-23 血中コレステロール低減剤

Country Status (1)

Country Link
JP (1) JP5818309B2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017105036A1 (de) * 2017-03-09 2018-09-13 Flexopharm Brain Gmbh & Co. Kg Mittel zur Anwendung bei der Behandlung der Dyslipidämie
KR102154124B1 (ko) * 2019-06-14 2020-09-09 고려대학교 산학협력단 프로피오니박테리움 프레우덴레키 mj2 균주를 유효성분으로 포함하는 대사성 질환 및 비만 관련 대사 이상의 예방, 치료, 또는 개선용 조성물
JP7402628B2 (ja) 2019-07-19 2023-12-21 株式会社明治 組成物
JP7402629B2 (ja) * 2019-07-19 2023-12-21 国立大学法人東京農工大学 プロピオン酸菌発酵物含有組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537242A (en) * 2002-06-21 2008-10-31 Newcastle Innovation Ltd Probiotic propionibacterium jensenii 702
US20100247500A1 (en) * 2007-11-27 2010-09-30 Kakuhei Isawa Agent and method for improving survivability of lactic acid bacterium, and food composition

Similar Documents

Publication Publication Date Title
Ng et al. Evaluation of probiotic potential of lactic acid bacteria isolated from traditional Malaysian fermented Bambangan (Mangifera pajang)
JP7387587B2 (ja) クロストリジウム・ディフィシル感染症の治療における新たな使用
RU2664479C2 (ru) Композиции и способы
Ooi et al. Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings
CN105979952B (zh) 协同细菌组合物以及其制造方法和用途
JP2016537410A5 (enExample)
US20180078588A1 (en) Compositions and methods for treatment of skin disorders
Watanabe et al. Prebiotic properties of epilactose
WO2012091081A8 (ja) 乳酸菌を含むインターフェロン産生誘導剤
FR2999601A1 (fr) Methode pour prevenir et/ou traiter les infections, colonisations ou maladies liees a staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis et/ou bacteroides fragilis
WO2009013709A3 (en) Zinc-enriched biomass, method for the preparation thereof and pro-biotic, cosmetic, dietary and nutraceutic products comprising the same
WO2009043856A3 (en) Modulation of tissue fatty acid composition of a host by human gut bacteria
JP2012201599A5 (enExample)
WO2009066537A1 (ja) 免疫調節性機能誘導剤及び食品組成物
JP2012057170A5 (enExample)
JP2015525572A5 (enExample)
JP2011504366A5 (enExample)
Del Piano et al. Assessment of the capability of a gelling complex made of tara gum and the exopolysaccharides produced by the microorganism Streptococcus thermophilus ST10 to prospectively restore the gut physiological barrier: a pilot study
JP2008538288A5 (enExample)
Lindström et al. Oral administration of live exopolysaccharide-producing Pediococcus parvulus, but not purified exopolysaccharide, suppressed Enterobacteriaceae without affecting bacterial diversity in ceca of mice
Lebeer et al. Topical cream with live lactobacilli modulates the skin microbiome and reduce acne symptoms
RU2012134407A (ru) Способ приготовления биомассы, содержащей плантарицин, и ее применение в медицинских целях
Sun et al. The anti-inflammatory potential of a strain of probiotic Bifidobacterium pseudocatenulatum G7: in vitro and in vivo evidence
JP2009232702A5 (enExample)
Awasthi et al. Gut dysbiosis and diabetic foot ulcer: role of probiotics